Trial Search Results

Aromatherapy for HSCT Distress

The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant (HSCT).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Stanford Nurse Alumnae

Stanford Investigator(s):

Intervention(s):

  • Other: Aromatherapy Inhaler

Phase:

N/A

Eligibility


Inclusion Criteria:

   - Autologous and Allogeneic patients admitted to E1 for planned HSCT

   - Patients with hematologic malignancies requiring HSCT

   - No allergies to lavender or peppermint essential oils

   - Must have received chemotherapy during preparative regimen (single or multi-agent
   regimen)

   - Adult patient over 18 years of age

   - Able to speak, read, and comprehend English

   - Willing and capable of providing informed consent

Exclusion Criteria:

   - Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion

   - Patients receiving a transplant for a germ cell tumor diagnosis

   - Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical
   deterioration)

   - Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4

   - History of scleroderma

   - History of atrial fibrillation

   - Known history of G6PD deficiency

   - Allergic to lavender or peppermint essential oils

   - Pediatric patient 18 years of age or less

   - Unable to speak, read, and comprehend English

   - Unwilling or incapable of providing informed consent

Ages Eligible for Study

19 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting